Health Care/Hospital News & Press Release Distribution

Health Care/Hospital

APAC
Global

Therabody, the Global Leader In Wellness Technology, Defends Against Recent Patent Infringement Lawsuit Filed by Hyperice

As the leading percussive patent owner and the driving force behind many of today's wellness innovations, Therabody will vigorously defend itself against the recent patent infringement lawsuit filed by Hyperice. LOS ANGELES, Jan. 5, 2024 /PRNewswire/ -- Therabody, the leader in tech wellness and...

2024-01-05 06:33 1718

Greenway Health Earns Frost & Sullivan's 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Products and Services that Enhance Health Providers and Patients Experiences

Greenway Health™ (Greenway®) offers groundbreaking client-centric electronic health record (EHR) and practice management software that streamline workflows and improve patient outcomes through a unique blend of in-depth insights and cutting-edge technology. SAN ANTONIO, Jan. 5, 2024 /PRNewswire/...

2024-01-05 04:30 2549

Greenway Health Earns Frost & Sullivan's 2023 North American Revenue Cycle Management Customer Value Leadership Award for Consistently Delivering Products and Services that Enhance Health Providers and Patients Experiences

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...

2024-01-05 00:19 2010

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the ...

2024-01-04 21:40 1758

OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients

* Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors * Proceeds to advance CUSP06, the company's antibody drug conjugate (ADC) targetingCDH6, to clinical proof-of-concept NEW YORK, Jan. 4, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc...

2024-01-04 21:11 1391

Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On December 28, 2023, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Vicagrel capsule, which is indicated to treat a range of thrombotic cardiova...

2024-01-04 21:05 1374

Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

- AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase 1 clinical study in advanced solid tumors - Avenzo also obtains an exclusive option to an additional preclinical program planned ...

2024-01-04 21:02 1443

GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held inSan Francisco, California, USA, from Ja...

2024-01-04 17:37 4160

GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference inSan Francisco, USA. The forum, themed " Innovations and Breakthroughs Shaping Tomorrow's Cell and Gene Therapi...

2024-01-04 16:55 1213

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis. * Derived from the platform, LAE105 is a potentially first-in-class drug candidate that depletes aHSC in the fibrotic liver by harnessing innate ...

2024-01-04 12:40 1210

Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference

MELBOURNE, Australia, Jan. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that DrChristian Behrenbruch, Managing Director and Group CEO, will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference inSan Francisco, CA (US). The pre...

2024-01-04 06:20 1569

IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies

SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 3, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products,today announced a new set of collaborations wi...

2024-01-04 05:30 1817

GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN

ADELAIDE, Australia, Jan. 3, 2024 /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase...

2024-01-04 04:30 1570

Mr. Chong-Yoon Lim, Chairman of COREE Group emphasizes "Creative destruction and Healthcare 4.0" [New Year Message at X-Twitter SNS]

SEOUL, South Korea, Jan. 3, 2024 /PRNewswire/ -- Chong-Yoon Lim, Chairman of COREE group, President of Hanmi pharmaceutical company and Former Chairman of Korea Biotechnology Industry Organization (The largest shareholder group of Coree HK, Hanmi (KOSPI) and Dx&Vx (KOSDAQ), as well), highlighted ...

2024-01-03 22:00 1845

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

* Company announces development of novel ionizable lipids and stabilizing components * eTurna™ delivery platform expected to improve safety, reduce immunogenicity * Customizable platform can be optimized to treat variety of cells, tissues and organs * Platform can accommodate different rou...

2024-01-03 22:00 1759

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, is pleased to anno...

2024-01-03 20:00 4601

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis...

2024-01-03 19:37 1355

Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A, independen...

2024-01-03 18:10 1487

Artificial Intelligence helps predict falls, creating safety system for patients

Solution alerts caregivers about unsteady gaits, making for prompt intervention. Trials in local healthcare institutions called promising. SINGAPORE, Jan. 3, 2024 /PRNewswire/ -- Applying AI technology to one of the main concerns in patient safety, Nanyang Polytechnic (NYP) and local medical te...

2024-01-03 16:00 1678

Guo Guangchang's New Year's Message: Steer Through the Rapids, Believe in the Future

HONG KONG, Jan. 3, 2024 /PRNewswire/ -- In the blink of an eye, 2023 is coming to an end. Thank you for your hard work and dedication. It has been a year of relentless efforts toward hope. After experiencing the three-year epidemic, many families have made plans for the new year from the beginni...

2024-01-03 11:35 5598

1 ... 41 42 434445 46 47 ... 805